UCL?Pfizer to develop stem cell sight therapies
UCL?Pfizer to develop pioneering stem cell sight therapies for age-related macular degeneration (AMD). – UCL has entered into a collaboration with the biopharmaceutical group Pfizer, negotiated by UCL Business, to advance development of stem cell-based therapies for age-related macular degeneration (AMD).